摘要
CD19嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)治疗已成为复发/难治性B细胞非霍奇金淋巴瘤(B-cell non-Hodgkin lymphoma,B-NHL)最具突破性的治疗策略之一。随着我国多款CD19 CAR-T产品获批并进入真实世界应用,如何规范患者筛选、优化治疗流程并最大化疗效与安全性,已成为当前临床实践面临的核心问题。国家肿瘤质控中心淋巴瘤质控专家委员会发布的《CD19 CAR-T治疗成人B细胞非霍奇金淋巴瘤管理实践专家共识(2025版)》系统规范了CAR-T治疗的全流程管理。本文结合最新循证医学证据与我国临床实践背景,对该共识的核心要点进行系统解读,以期促进CAR-T治疗在我国B-NHL领域的规范化与高质量应用。
CD19 chimeric antigen receptor T-cell(CAR-T)therapy has emerged as one of the most transformative therapies for patients with relapsed/refractory(r/r)B-cell non-Hodgkin lymphoma(B-NHL).With multiple CD19 CAR-T products approved in China and increasingly adopted in real-world clinical practice,the standardization of patient selection,optimization of treatment pathways,and maximization of both efficacy and safety have become major challenges in contemporary clinical care.In this context,the Lymphoma Expert Committee of National Cancer Quality Control Center issued the Expert Consensus on the Management Practice of CD19 CAR-T Cell Therapy for B-Cell Lymphoma in China(2025 Edition),which provides a systematic framework for the full-process management of CAR-T therapy.Integrating the latest evidence-based medical data with the Chinese clinical practice setting,this article offers a structured interpretation of the key recommendations outlined in the consensus,with the aim of promoting the standardized and high-quality implementation of CAR-T therapy for B-NHL in China.
作者
翁华伟
范加维
林桐榆
Weng Huawei;Fan Jiawei;Lin Tongyu(Department of Medical Oncology,Sichuan Clinical Research Center for Cancer,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,University of Electronic Science and Technology of China,Chengdu 610041,Sichuan,China;General Department,Sichuan Clinical Research Center for Cancer,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,University of Electronic Science and Technology of China,Chengdu 610041,Sichuan,China)
出处
《肿瘤预防与治疗》
2026年第1期1-4,共4页
Journal of Cancer Control And Treatment
基金
国家自然科学基金区域创新发展联合基金重点项目(编号:U24A20679)
国家自然科学基金面上项目(编号:82470237)。
关键词
B细胞非霍奇金淋巴瘤
嵌合抗原受体T细胞
指南解读
B-cell non-Hodgkin lymphoma
Chimeric antigen receptor T-cell therapy
Guideline interpretation
